Article
Navigating the bumpy road ahead: stakeholder perspectives on EU HTAR
This article was originally published on The Evidence Base.
As the European Union's Health Technology Assessment Regulation (EU HTAR) prepares to take effect on January 12, 2025, stakeholders across the healthcare ecosystem are faced with a pivotal opportunity to reshape the evaluation and adoption of new medicines and health technologies. The regulation promises a harmonized framework for assessing clinical evidence, reducing redundancies across Member States, and fostering collaboration in health technology assessment. However, the path to achieving these ambitious goals is neither straightforward nor without challenges.
During ISPOR Europe 2024, Herbert Altmann, Vice President, Market Access and Healthcare Consulting Europe at Cencora, led an informative session exploring the topic, “Ready for 2025? How Lessons Learned From National System Reforms Can Guide Our Response to the New EU HTA Regulations.” The discussion focused on recent HTA reforms in Germany, Spain, France and Poland, examining stakeholder readiness for the EU HTAR and how shared experiences can enhance preparedness.
Altmann was joined by an expert panel: Iga Lipska, Chairwoman of the Board at the Health Policy Institute Poland; François Meyer, Former Director at Haute Autorité de Santé (HAS); Oriol Solà-Morales, CEO of Fundació HiTT; Mihai Rotaru, Director Market Access at the European Federation of Pharmaceutical Industries and Associations (EFPIA); and Max Brosa, former Managing Director of Pharmalex Spain.
Altmann was joined by an expert panel: Iga Lipska, Chairwoman of the Board at the Health Policy Institute Poland; François Meyer, Former Director at Haute Autorité de Santé (HAS); Oriol Solà-Morales, CEO of Fundació HiTT; Mihai Rotaru, Director Market Access at the European Federation of Pharmaceutical Industries and Associations (EFPIA); and Max Brosa, former Managing Director of Pharmalex Spain.
